The highly potent and allosteric pan-AKT inhibitor MK-2206 has also been associated with similar results in another phase I trial, in combination with fulvestrant, anastrozole, or both, among patients with HR-positive, HER2-negative breast cancer [40]. The gene discussed is AKT1; the disease is breast cancer.